{"id":"W4394769738","doi":"10.1016/j.esmoop.2024.102974","title":"Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer","year":2024,"lang":"en","type":"article","venue":"ESMO Open","topic":"Breast Cancer Treatment Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":17,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Samsung; Society for Immunotherapy of Cancer; Pfizer Japan; Sun Pharma; European Society for Medical Oncology; Fondazione Beretta; Eisai; Astellas Pharma; Eli Lilly and Company; Ono Pharmaceutical; Novartis; Bayer Yakuhin; Veracyte; Boehringer Ingelheim Japan; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; Chugai Pharmaceutical; Roche; Intas Pharmaceuticals; Relay Therapeutics; Amgen; Pfizer; Institute for Oil Sands Innovation, University of Alberta; AstraZeneca","keywords":"Reimbursement; Breast cancer; Medicine; Family medicine; China; Alternative medicine; South asia; Clinical Practice; Clinical trial; Cancer; Internal medicine; Health care; Political science; Pathology","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01628087,0.001171931,0.001416958,0.004945331,0.001186237,0.002700013,0.00313587,0.00502425,0.01121771],"category_scores_gemma":[0.0576839,0.0006962652,0.003706652,0.004329586,0.001177413,0.002121206,0.003557046,0.005469874,0.009782273],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004058883,"about_ca_system_score_gemma":0.02140961,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01554673,"about_ca_topic_score_gemma":0.02788505,"domain_scores_codex":[0.9802284,0.008682746,0.005622228,0.0006157656,0.003985126,0.0008657668],"domain_scores_gemma":[0.9471571,0.007041755,0.004687589,0.001317242,0.03777223,0.002024066],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001854751,0.0002055395,0.004393457,0.008247527,0.0002256211,0.0008164829,0.001365254,0.000808211,0.001107431,0.004778747,0.7420807,0.2357855],"study_design_scores_gemma":[0.0002038876,0.0001140935,0.008232056,0.02455114,0.0002376558,0.001494793,0.0008765209,0.0005925483,0.0005655891,0.004807205,0.9582222,0.0001022944],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"other","genre_scores_codex":[0.01023806,0.167366,0.09273621,0.3858369,0.0342026,0.02289323,0.03304638,0.002511711,0.2511689],"genre_scores_gemma":[0.06469371,0.2398277,0.3882583,0.1295914,0.007903442,0.03319496,0.05739674,0.001060513,0.07807322],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.01628087,"threshold_uncertainty_score":0.08610255,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05948405414798169,"score_gpt":0.4030207663022943,"score_spread":0.3435367121543126,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}